Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's ...

Eli Lilly and Company and Purdue University are keeping their partnership alive beyond it’s previously expected years. In an ...

Efforts to reduce diabetes in three Indianapolis neighborhoods are deemed successful, addressing access, education, and trust.

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

The move is part of Roche’s previously announced plan to invest $50 billion in pharmaceuticals and diagnostics over the next ...